NPI: 1376511618 · MIAMI BEACH, FL 33139 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/11/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/11/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 10,552 | $962K |
| 2019 | 15,813 | $1.26M |
| 2020 | 10,914 | $1.11M |
| 2021 | 9,736 | $517K |
| 2022 | 9,898 | $308K |
| 2023 | 1,851 | $65K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 18,948 | 1,115 | $1.69M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 20,656 | 828 | $1.19M |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,768 | 659 | $583K |
| A4657 | Syringe, with or without needle, each | 2,735 | 940 | $320K |
| J1756 | Injection, iron sucrose, 1 mg | 2,535 | 363 | $138K |
| 85041 | 723 | 420 | $64K | |
| 85048 | 614 | 355 | $57K | |
| 83970 | 382 | 198 | $41K | |
| 83540 | 394 | 239 | $37K | |
| 83550 | 394 | 239 | $36K | |
| 82728 | 336 | 207 | $30K | |
| 82108 | 223 | 148 | $23K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 56 | 29 | $6K |